In this context, the most common KMT2A fusion partners in our series of i-AML are: MLLT3/AF9 (35.7%), MLLT1/ENL (15.3%), MLLT4/AF6 (14.1%), MLLT10/AF10 (10%), AFF1/AF4 and MLL-PTD (6.1%). This evidence concerns the gene AFDN and acute myeloid leukemia.